Novo Nordisk A/S (NYSE:NVO) Shares Sold by Hardman Johnston Global Advisors LLC

Hardman Johnston Global Advisors LLC lessened its position in Novo Nordisk A/S (NYSE:NVO) by 3.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 144,198 shares of the company’s stock after selling 4,580 shares during the period. Hardman Johnston Global Advisors LLC’s holdings in Novo Nordisk A/S were worth $17,170,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC increased its stake in shares of Novo Nordisk A/S by 14.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after purchasing an additional 37,346 shares during the period. Private Wealth Partners LLC increased its stake in shares of Novo Nordisk A/S by 155.1% in the third quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock valued at $3,953,000 after purchasing an additional 20,188 shares during the period. Independence Bank of Kentucky increased its stake in shares of Novo Nordisk A/S by 192.7% in the third quarter. Independence Bank of Kentucky now owns 11,490 shares of the company’s stock valued at $1,368,000 after purchasing an additional 7,565 shares during the period. Traynor Capital Management Inc. increased its stake in shares of Novo Nordisk A/S by 3.4% in the third quarter. Traynor Capital Management Inc. now owns 305,404 shares of the company’s stock valued at $36,364,000 after purchasing an additional 10,019 shares during the period. Finally, Cetera Investment Advisers increased its stake in shares of Novo Nordisk A/S by 453.3% in the first quarter. Cetera Investment Advisers now owns 265,538 shares of the company’s stock valued at $34,095,000 after purchasing an additional 217,545 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $110.15 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The company has a 50-day moving average of $123.24 and a 200-day moving average of $130.76. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The firm has a market cap of $494.30 billion, a price-to-earnings ratio of 37.72, a price-to-earnings-growth ratio of 1.46 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The business had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. Analysts forecast that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NVO. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, October 10th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.